Metabolic hypogonadism, a condition marked by low testosterone levels and frequently seen in obese individuals, contributes to worsening metabolic health and an increased risk of type 2 diabetes.

Weight-loss drugs like semaglutide and tirzepatide may help shrink waistlines, but new research shows they fail to boost ...

Landmark trials have shown that GLP-1 receptor agonists, originally developed for diabetes and weight loss, also provide ...

The study found that weight regain varied with follow-up, with participants experiencing weight regain at eight, 12, and 20 ...

Tirzepatide outperformed semaglutide in simultaneously achieving four key therapeutic targets for type 2 diabetes.

With semaglutide and tirzepatide dosed once weekly, their estimated average yearly costs in the U.S. are $14,080 and $8,126, respectively. What's more, obesity alone as an indication bars coverage ...

Tirzepatide is more effective than semaglutide for weight loss, according to a new study on GLP-1 medications ; The study was funded by Eli Lilly, the pharmaceutical company that manufactures ...

The resolution of shortages for tirzepatide and other GLP-1 medications, such as semaglutide, signals a potential shift toward increased FDA enforcement as the agency works to align industry ...

How GLP-1 Agonists Might Help With Sleep Apnea. Both semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are GLP-1 agonists, which are medications that help to lower blood sugar ...

You may still prescribe compounded GLP-1 drugs, but your prescription must clearly articulate a medically necessary significant difference from the commercially available drug product. Cost ...

New research links semaglutide and tirzepatide, which are GLP-1 agonists used to treat type 2 diabetes and aid weight loss, to a rare eye disease that may cause vision loss.